SCHEMBL6799478

SCHEMBL6799478

C=CCC(c1ccccc1C(=O)O)c1c[nH]c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 11/20 0.48
GAA P10253 11/20 0.48
SI P14410 11/20 0.48
MGAM2 Q2M2H8 11/20 0.48
GPR84 Q9NQS5 3/20 0.48
HDAC3 O15379 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
HDAC4 P56524 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
FFAR1 O14842 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704428 0.83 MGAM (0.43) MGAMGAASIMGAM2GPR84
SCHEMBL2465013 0.79 SLC6A2 (0.57) MGAMGAASIMGAM2GPR84
SCHEMBL8895798 0.73 CYP2C19 (0.47) GAAHDAC8KMT2AMAPT
SCHEMBL2995918 0.72 HTR2A (0.51) GPR84FFAR1MEN1KMT2AMAPT
SCHEMBL1226003 0.71 KMT2A (0.49) MGAMGAASIMGAM2GPR84
Hydrazine SCHEMBL27559974 0.70 ALDH1A1 (0.72) GPR84MEN1KMT2A
SCHEMBL4089990 0.70 CYP2C19 (0.45) GAAHDAC8MEN1KMT2AMAPT
SCHEMBL64182 0.70 GPR84 (0.77) GPR84MEN1KMT2A
SCHEMBL9309358 0.70 HTR2A (0.56) MGAMGAASIMGAM2GPR84
SCHEMBL6283244 0.70 GPR84 (0.59) MGAMGAASIMGAM2GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186300-A1 Process for the preparation of zafirlukast FINETECH LABORATORIES LTD. (IL) 2004-09-23 US claimed
WO-2002046153-A2 PROCESS FOR THE PREPARATION OF ZAFIRLUKAST FINETECH LABORATORIES LTD. (IL) 2002-06-13 WO claimed
US-20040186300-A1 Process for the preparation of zafirlukast FINETECH LABORATORIES LTD. (IL) 2004-09-23 US disclosed
US-20040186300-A1 Process for the preparation of zafirlukast FINETECH LABORATORIES LTD. (IL) 2004-09-23 US disclosed
WO-2002046153-A3 PROCESS FOR THE PREPARATION OF ZAFIRLUKAST FINETECH LAB LTD (IL) 2002-09-06 WO disclosed
WO-2002046153-A2 PROCESS FOR THE PREPARATION OF ZAFIRLUKAST FINETECH LABORATORIES LTD. (IL) 2002-06-13 WO disclosed
WO-2002046153-A2 PROCESS FOR THE PREPARATION OF ZAFIRLUKAST FINETECH LABORATORIES LTD. (IL) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186300-A1 Process for the preparation of zafirlukast LTC4S, LTB4R, CMA1 MGAM 1819/4885GAA 1916/4885SI 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.